FSD Pharma adds David Urban to Board of Directors
FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of David Urban to the Company’s Board of Directors.
Tag: medical cannabis
FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint
FSD Pharma Inc. (“FSD Pharma” or the “Company“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) has been migrated to the Cannabis Act and its regulations, effective November 8, 2018. The issuance of the new cannabis license includes the ability to sell cannabis to other licensed producers in accordance with subsection 11(5) of the Cannabis Regulations.
FSD Pharma Announces Positive ISA Report for “Steady Stomach” CBD Combination
FSD Pharma Inc. (“FSD Pharma“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann“) received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy, the basis of its “Steady Stomach” product.
FSD Pharma Announces Launch of IBS Clinical Study
FSD Pharma Inc. (“FSD Pharma” or “FSD“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics (“SciCann“). The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy results from a preclinical study in rodent models which demonstrated a three-fold increased efficacy in lowering abdominal inflammation levels with the advanced combination product as compared to CBD alone.
Canntab to Enter Medicinal Cannabis Market in Mexico
Letter of Intent with Labsco Promedic SA de CV of Mexico
FSD Pharma Announces Appointments of Dr. Raza Bokhari as Interim CEO and Co-Chairman, Anthony Durkacz as Co-Chairman and Zeeshan Saeed as President
The Board of Directors of FSD Pharma Inc. (“FSD Pharma” or the “Company“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce the appointment of Dr. Raza Bokhari as interim CEO and Co-Chairman of the Board of Directors, replacing Thomas Fairfull.
FSD Pharma announces issuance of cannabis license under Excise Act
FSD Pharma Inc. (“FSD Pharma” or the “Company“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the Company’s application for a cannabis license under the Excise Tax Act has been conditionally approved by the Canada Revenue Agency (the “CRA“) and is effective as of October 17, 2018. The issuance of a cannabis license by the CRA is a requirement to sell cannabis and is a prerequisite to obtaining a sales license under the Cannabis Act.
FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, aNASDAQ Traded Pharmaceutical Company Focusing on the Development ofCannabinoid-Based Treatments, to Create Medical Cannabis IndustryInnovator
Transaction combines two highly complementary businesses; the significant production and distribution of medical and recreational products by FSD Pharma, and the premium and differentiated medical and pharmaceutical brands by Therapix Biosciences;
Canntab Files Application to Become Licensed Producer
Canntab Therapeutics Limited (CSE: PILL) (“Canntab” or the “Company“) a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the “License“), and that it received confirmation from Health Canada that its application had been received. The License, if granted by Health Canada, would allow the Company to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new purpose-built facility.
FSD Pharma Featured on CTV Toronto
FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) is pleased to provide shareholders and interested parties with a link to the CTV Toronto program segment featuring interviews with executives and employees at the Company’s facility in Cobourg. In the segment, CEO and President Thomas Fairfull, Director Anthony Durkacz, and EVP and Director Zeeshan Saeed discuss job creation and the Company.